TABLE 1.
Characteristics of the Saprochaete cases.
| Characteristics | Cases N (%) | Controls N (%) |
| Sex female add a line with number of male patients and controls? | 1 (14.3) | 17 (48.6) |
| Mean age (SD) | 41.1 (26.1) | 51.0 (22.0) |
| Age in range | ||
| 0–40 | 3 (42.7) | 8 (22.3) |
| 41–50 | 1 (14.3) | 4 (11.4) |
| 51–60 | 1 (14.3) | 9 (25.7) |
| 61–70 | 2 (28.6) | 10 (28.6) |
| >70 | – | 4 (11.4) |
| Transfer to other UO what is UO? | 2 (28.6) | 10 (28.6) |
| Underlying diseases or conditions | ||
| Acute myeloid leukemia | 2 (28.6) | 10 (28.6) |
| Chronic myeloid leukemia | – | 2 (5.7) |
| Lymphoma | 2 (28.6) | 14 (40.0) |
| Multiple myeloma | – | 3 (8.6) |
| Other | 3 (42.9) | 6 (17.1) |
| Charlson co-morbidity score, media (DS) | 3 (1.8) | 4.3 (2.0) |
| Charlson score in range | ||
| 0–3 | 4 (57.1) | 11 (31.4) |
| 4–7 | 3 (42.9) | 21 (60.0) |
| 8–11 | – | 3 (8.6) |
| Barthel scale, mean (SD) | 86.7 (21.8) | 88.2 (19.6) |
| Dead, N(%) | 3 (42.9) | 2 (5.7) |
| Presence of CVC during recovery | 7 (100) | 32 (31.4) |
| Days with CVC | ||
| 0–20 | 2 (28.6) | 18 (51.4) |
| 21–40 | – | 10 (28.6) |
| >40 | 5 (71.4) | 7 (20.0) |
| Days of CVC, mean (IQR) | 64(18–78) | 20(15–30) |
| Mechanical ventilation | 1 (14.3) | 2 (5.7) |
| Bladder catheter | 3 (42.9) | 9 (25.7) |
| Chemotherapy | 7 (100) | 29 (82.9) |
| Immunosuppression | 7 (100) | 24 (68.6) |
| Antibiotics | 7 (100) | 33 (94.3) |
| Aminoglycosides | 6 (85.7) | 11 (31.4) |
| Days with aminoglycosides, mean (SD) | 11.4 (11.6) | 0 (0.7) |
| Penicillin with beta-lactamases inhibitor | 5 (71.4) | 17 (48.6) |
| Days with penicillin with BL inhibitor, mean (SD) | 5.5 (5.1) | 4.0 (5.9) |
| Cephalosporins 3–4° gen. | 3 (42.9) | 13 (37.1) |
| Days with cephalosporins 3–4° gen., mean (SD) | 7.1 (11.7) | 3.9 (7.1) |
| Fluorochinolons | 2 (28.2) | 13 (37.1) |
| Days with fluorochinolons, mean (SD) | 3.8 (9.4) | 7.0 (11.1) |
| Glycopeptides, N(%) | 4 (57.1) | 9 (25.7) |
| Days with glycopeptides, mean(SD) | 8.4 (12.0) | 2.7(85.2) |
| Meropenem | 5 (71.4) | 5 (14.3) |
| Days with meropenem, mean (SD) | 7.3 (10.0) | 2.1 (8.6) |
| Co-trimoxazole | 1 (14.3) | 5 (14.3) |
| Days with co-trimoxazole, mean (SD) | 0.3 (0.8) | 0.6 (1.7) |
| Antifungals | 4 (57.1) | 26 (74.3) |
| Amphotericin | 3 | 4 |
| Days with amphotericin B, mean (SD) | 2.9 (4.3) | 2.6 (9.9) |
| Azols | 2 | 25 |
| Days with azols, mean (SD) | 9.4 (19.5) | 13.6 (11.5) |
| Echinocandins | 2 | 2 |
| Days with echinocandins, mean (SD) | 3 (5.5) | 0.4 (1.8) |
| HSCT | 2 (28.6) | 8 (22.9) |
| Days from the HSCT, mean (SD) | 33 (22.6) | 20.1 (9.0) |
| Proton pump inhibitors (PPI) | 4 (57.1) | 24 (68.6) |
| Neutropenia | 7 (100) | 30 (85.7) |
| Nadir of neutrophils, mean (DS) | 11.4 (3.89) | 121 (262.5) |
| Days with neutropenia, mean (DS) | 23 (15.1) | 9.9 (6.8) |
| Days with neutropenia in range | ||
| 0–10 | 3 (42.3) | 18 (60.0) |
| 11–20 | – | 10 (33.3) |
| >20 | 4 (57.1) | 2 (6.7) |
| Growth factors | 5 (71.4) | 21 (60.0) |
| Mucositis | 3 (42.9) | 7 (20.0) |
| Diarrhea | 6 (85.7) | 17 (48.6) |
| Transfusion with RC | 7 (100) | 30 (85.7) |
| Number of red cell transfusion, mean (SD) | 12.4 (9.7) | 4.1 (3.3) |
| Plasma transfusion | 4 (57.1) | 4 (11.4) |
| Number of plasma transfusion, mean (SD) | 3.1 (3.5) | 0.3(1.0) |
| Platelet transfusion | 7 (100) | 26 (74.3) |
| Number of platelet transfusion, mean (SD) | 14.4(11.7) | 2.8(3.6) |